Company: OCEA
Filing Date: 2025-04-08
Form Type: 10-K
Source: 0001641172-25-003155
Chunk: 2624

Company: Ocean Biomedical, Inc.
Filing Date: 2025-04-08
Form: 10-K
Item: Item 1
Chunk 2624
---
 study, we may be limited in our ability to capitalize on the market potential of
these inventions or developments.

99

Third
parties may assert that we are employing their proprietary technology without authorization.

There
may be third-party patents of which we are currently unaware with claims to compositions of matter, materials, formulations, methods
of manufacture or methods for treatment that encompass the composition, use or manufacture of our product candidates. There may be currently
pending patent applications of which we are currently unaware which may later result in issued patents that our product candidates or
their use or manufacture may infringe. In addition, third parties may obtain patents in the future and claim that use of our technologies
infringes upon these patents. If any third-party patent were held by a court of competent jurisdiction to cover our product candidates,
intermediates used in the manufacture of our product candidates or our materials generally, aspects of our formulations or methods of
use, the holders of any such patent may be able to block our ability to develop and commercialize the product candidate unless we obtained
a license or sublicense or until such patent expires or is finally determined to be held invalid or unenforceable. In either case, such
a license or sublicense may not be available on commercially reasonable terms or at all. If we are unable to obtain a necessary license
or sublicense to a third-party patent on commercially reasonable terms, or at all, our ability to commercialize our product candidates
may be impaired or delayed, which could in turn significantly harm our business. Even if we obtain a license or sublicense, it may be
nonexclusive, thereby giving our competitors access to the same technologies licensed or sublicensed to us. In addition, if the breadth
or strength of protection provided by our patents and patent applications is threatened, it could dissuade companies from collaborating
with us to license, sublicense, develop or commercialize current or future product candidates.

Parties
making claims against us may seek and obtain injunctive or other equitable relief, which could effectively block our ability to further
develop and commercialize our product candidates. Defense of these claims, regardless of their merit, would involve substantial litigation
expense and would be a substantial diversion of employee resources from our business. In the event of a successful claim of infringement
against us, we may have to pay substantial damages, including treble damages and attorneys’ fees for willful infringement, obtain
one or more licenses or sublicenses from third parties, pay royalties or redesign our infringing products, which